{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:05:11Z","timestamp":1787018711726,"version":"build-2736575974"},"reference-count":98,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>The increasing specificity of novel druggable targets coupled with the complexity of emerging therapeutic modalities for treating human diseases has created a growing need for nonhuman primates (NHPs) as models for translational drug discovery and nonclinical safety assessment. In particular, NHPs are critical for investigating potential unexpected\/undesired on-target and off-target liabilities associated with administration of candidate biotherapeutics (nucleic acids, proteins, viral gene therapy vectors, etc.) to treat nervous system disorders. Nervous system findings unique to or overrepresented in NHPs administered biomolecule-based (\u201cbiologic\u201d) test articles include mononuclear cell infiltration in most neural tissues for all biomolecule classes as well as neuronal necrosis with glial cell proliferation in sensory ganglia for certain viral vectors. Such test article-related findings in NHPs often must be differentiated from procedural effects (e.g., local parenchymal or meningeal reactions associated with an injection site or implanted catheter to administer a test article directly into the central nervous system) or spontaneous background findings (e.g., neuronal autophagy in sensory ganglia).<\/jats:p>","DOI":"10.1177\/01926233221101314","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T08:11:27Z","timestamp":1655107887000},"page":"693-711","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Society of Toxicologic Pathology Neuropathology Interest Group Article: Neuropathologic Findings in Nonhuman Primates Associated With Administration of Biomolecule-Based Test Articles"],"prefix":"10.1177","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-1146","authenticated-orcid":false,"given":"Dinesh S.","family":"Bangari","sequence":"first","affiliation":[{"name":"Global Discovery Pathology, Translational In-Vivo Models Platform, Sanofi, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Lanigan","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Ashland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-3260","authenticated-orcid":false,"given":"Felix","family":"Goulet","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Senneville, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2956","authenticated-orcid":false,"given":"Silvia","family":"Siso","sequence":"additional","affiliation":[{"name":"Translational Imaging and Pathology, Codiak BioSciences, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-1492","authenticated-orcid":false,"given":"Brad","family":"Bolon","sequence":"additional","affiliation":[{"name":"GEMpath, Inc., Longmont, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4152"},{"key":"e_1_3_3_3_2","unstructured":"Thorpe KL Levey AI Thomas J. The U.S. burden of neurodegenerative disease. Published 2021. Accessed March 4 2022. https:\/\/www.fightchronicdisease.org\/resources\/us-burden-neurodegenerative-disease."},{"key":"e_1_3_3_4_2","unstructured":"PhRMA (Pharmaceutical Research and Manufacturers of America). Medicines in development for neurodegenerative diseases\u20142021 report. Published 2021. Accessed March 4 2022. https:\/\/phrma.org\/resource-center\/Topics\/Medicines-in-Development\/Medicines-in-Development-for-Neurodegenerative-Diseases-2021-Report."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813279"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6678422"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.148"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2019.1630415"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020092"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00835"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X01666160930121647"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.06.001"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.090"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.09.011"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.579062"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.013"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2019.v109i8b.14009"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.696434"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.03.033"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113972"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-021-00650-0"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801271"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.08.037"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-021-00390-6"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.12.013"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2018.08.004"},{"key":"e_1_3_3_27_2","unstructured":"ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). M3(R2): Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Published 2009. Accessed February 28 2022. https:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf."},{"key":"e_1_3_3_28_2","unstructured":"ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). S6(R1): Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Published 2011. Accessed February 28 2022. https:\/\/database.ich.org\/sites\/default\/files\/S6_R1_Guideline_0.pdf."},{"key":"e_1_3_3_29_2","unstructured":"EMA (European Medicines Agency). Guidelines relevant for advanced therapy medicinal products. Published 2016. Accessed March 4 2022. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000298.jsp."},{"key":"e_1_3_3_30_2","unstructured":"FDA (U.S. Food and Drug Administration). Guidance for industry: preclinical assessment of investigational cellular and gene therapy products. Published 2013. Accessed March 4 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/preclinical-assessment-investigational-cellular-and-gene-therapy-products."},{"key":"e_1_3_3_31_2","unstructured":"FDA (U.S. Food and Drug Administration). Cellular & gene therapy guidances. Published 2016. Accessed March 4 2022. https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/cellular-gene-therapy-guidances."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmod.2017.11.005"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1992"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature11128"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3707"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313510987"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314526475"},{"key":"e_1_3_3_38_2","first-page":"775","volume-title":"Haschek and Rousseaux\u2019s Handbook of Toxicologic Pathology","author":"Chilton JA","unstructured":"Chilton JA, Laing ST, Bradley A. Animal models in toxicologic research\u2014nonhuman primates. In: Haschek WM, Rousseaux CG, Wallig MA, et al., eds. Haschek and Rousseaux\u2019s Handbook of Toxicologic Pathology. Vol 1. 4th ed. San Diego: Academic Press (Elsevier); 2022:775-807.","edition":"4"},{"key":"e_1_3_3_39_2","unstructured":"Bluemel J Korte S Schenck E Weinbauer GF. The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment. San Diego: Academic Press (Elsevier); 2015."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw072"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/019262330002800103"},{"key":"e_1_3_3_42_2","volume-title":"The Primate Nervous System, Part I","author":"Bloom FE","year":"1997","unstructured":"Bloom FE, Bj\u00f6rklund A, H\u00f6kfelt T. The Primate Nervous System, Part I. Vol 13. Amsterdam: Elsevier; 1997."},{"key":"e_1_3_3_43_2","volume-title":"The Primate Nervous System, Part II","author":"Bloom FE","year":"1998","unstructured":"Bloom FE, Bj\u00f6rklund A, H\u00f6kfelt T. The Primate Nervous System, Part II. Vol 14. Amsterdam: Elsevier; 1998."},{"key":"e_1_3_3_44_2","volume-title":"The Primate Nervous System, Part III","author":"Bloom FE","year":"1999","unstructured":"Bloom FE, Bj\u00f6rklund A, H\u00f6kfelt T. The Primate Nervous System, Part III. Vol 15. Amsterdam: Elsevier; 1999."},{"key":"e_1_3_3_45_2","volume-title":"Primate Brain Maps: Structure of the Macaque Brain","author":"Martin RF","year":"2000","unstructured":"Martin RF, Bowden DM. Primate Brain Maps: Structure of the Macaque Brain. Amsterdam: Elsevier; 2000."},{"key":"e_1_3_3_46_2","unstructured":"Mikula S Trotts I Stone JS Jones EG. Brain maps. University of California. Published 2005. Accessed March 4 2022. http:\/\/brainmaps.org\/."},{"key":"e_1_3_3_47_2","volume-title":"Primate Brain Maps: Structure of the Macaque Brain","author":"Wu J","year":"2000","unstructured":"Wu J, Bowden DM, Dubach MF, Robertson JE. Primate Brain Maps: Structure of the Macaque Brain. New York: Elsevier; 2000."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4362"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12469"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310390231"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2008.05.002"},{"key":"e_1_3_3_52_2","volume-title":"de Lahunta\u2019s Veterinary Neuroanatomy and Clinical Neurology","author":"de Lahunta A","year":"2020","unstructured":"de Lahunta A, Glass EN, Kent M. de Lahunta\u2019s Veterinary Neuroanatomy and Clinical Neurology. 5th ed. Philadelphia: Elsevier; 2020."},{"key":"e_1_3_3_53_2","unstructured":"ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). Safety pharmacology studies for human pharmaceuticals. S7A. Published 2000. Accessed March 4 2022. https:\/\/database.ich.org\/sites\/default\/files\/S7A_Guideline.pdf."},{"key":"e_1_3_3_54_2","first-page":"77","volume-title":"Haschek and Rousseaux\u2019s Handbook of Toxicologic Pathology","author":"Yadav DB","unstructured":"Yadav DB, Gadkar K, Figueroa I. Biotherapeutics ADME and PK\/PD principles. In: Haschek WM, Rousseaux CG, Wallig MA, et al., eds. Haschek and Rousseaux\u2019s Handbook of Toxicologic Pathology. Vol 1. 4th ed. San Diego: Academic Press (Elsevier); 2022:77-100.","edition":"4"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312474865"},{"key":"e_1_3_3_56_2","first-page":"312","volume-title":"Encyclopedia of the Neurological Sciences","author":"Bolon B","unstructured":"Bolon B, Butt MT. Fixation and processing of central nervous system tissue. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences. Vol 2. 2nd ed. Oxford: Academic Press; 2014:312-316.","edition":"2"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318772484"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623317720120"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623317749453"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623311436180"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319850774"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470939956"},{"key":"e_1_3_3_63_2","first-page":"379","volume-title":"The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment","author":"Cauvin AJ","unstructured":"Cauvin AJ, Peters C, Brennan F. Advantages and limitations of commonly used nonhuman primate species in research and development of biopharmaceuticals. In: Bluemel J, Korte S, Schenck E, Weinbauer GF, eds. The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment. San Diego: Academic Press (Elsevier); 2015:379-395."},{"key":"e_1_3_3_64_2","volume-title":"Greenfield\u2019s Neuropathology","author":"Love S","year":"2015","unstructured":"Love S, Budka H, Ironside JW, Perry A. Greenfield\u2019s Neuropathology. 9th ed. Boca Raton: CRC Press (Taylor & Francis); 2015.","edition":"9"},{"key":"e_1_3_3_65_2","volume-title":"Spontaneous Pathology of the Laboratory Non-human Primate","author":"Bradley AE","year":"2022","unstructured":"Bradley AE, Chilton J. Spontaneous Pathology of the Laboratory Non-human Primate. San Diego: Academic Press (Elsevier); 2022."},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1389364"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319867322"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312439125"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1293\/tox.34.1S"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320951154"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.167"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.01.013"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.116"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310397557"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319862540"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319857053"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310378869"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:NEUR.0000011333.06638.b6"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2006.03.002"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-008-0386-y"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/01926233211063831"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318791801"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-021-03255-8"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300985820959231"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310391679"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1080\/01926230390174995"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314551840"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318821332"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.06.004"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314537723"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300985812450719"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315623265"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316642527"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310387619"},{"key":"e_1_3_3_97_2","volume-title":"Nonhuman Primates in Biomedical Research. Vol 1: Biology and Management","author":"Abee CR","year":"2012","unstructured":"Abee CR, Mansfield K, Tardif S, Morris T. Nonhuman Primates in Biomedical Research. Vol 1: Biology and Management. 2nd ed. San Diego: Academic Press (Elsevier); 2012.","edition":"2"},{"key":"e_1_3_3_98_2","volume-title":"Nonhuman Primates in Biomedical Research. Vol 2: Diseases","author":"Abee CR","year":"2012","unstructured":"Abee CR, Mansfield K, Tardif S, Morris T. Nonhuman Primates in Biomedical Research. Vol 2: Diseases. 2nd ed. San Diego: Academic Press (Elsevier); 2012.","edition":"2"},{"key":"e_1_3_3_99_2","volume-title":"The Common Marmoset in Captivity and Biomedical Research","author":"Marini RP","year":"2019","unstructured":"Marini RP, Wachtman LM, Tardif SD, Mansfield K, Fox JG. The Common Marmoset in Captivity and Biomedical Research. San Diego: Academic Research (Elsevier); 2019."}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233221101314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/01926233221101314","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233221101314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:42:45Z","timestamp":1777653765000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/01926233221101314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1177\/01926233221101314"],"URL":"https:\/\/doi.org\/10.1177\/01926233221101314","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}